drugset / Trial / NCT00606099

Efficacy and Safety of Telbivudine in Patients With Chronic Hepatitis B

NCT00606099

Phase 4 Withdrawn Novartis
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to evaluate the efficacy and safety of telbivudine 600mg versus adefovir dipivoxil 10mg in patients with compensated chronic hepatitis B.

Timeline

Start
2007-11
Primary completion
2009-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adefovir dipivoxil Small molecule 10 mg
Subject Telbivudine Small molecule 600 mg